New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
15:54 EDTDHR, JNJ, BX, CGCarlyle in lead to buy J&J ortho clinical diagnostics unit, Reuters says
Johnson & Johnson (JNJ) currently views a bid from Carlyle Group (CG) for its ortho clinical diagnostics unit as superior to a rival bid from Blackstone Group (BX) in partnership with conglomerate Danaher (DHR), three people familiar with the matter said, according to Reuters, which added that the price of Carlyle's offer could not be learned. Reference Link
News For JNJ;CG;BX;DHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 27, 2015
08:15 EDTJNJJohnson & Johnson would benefit from Pharmacyclics deal, says Wells Fargo
After Bloomberg and The Financial Times reported that Johnson & Johnson (JNJ) and Novartis (NVS) are interested in buying Pharmacyclics (PCYC), Wells Fargo thinks the deal would cause a slight acceleration of Johnson & Johnson's revenue growth. The firm believes that the deal could be slightly dilutive to Johnson & Johnson's EPS in the first full year and 1%-4% accretive thereafter. Wells keeps an Outperform rating on Johnson & Johnson.
February 26, 2015
12:56 EDTBXKKR's Samson in restructuring talks, WSJ says
KKR's (KKR) Samson Resources is in discussions with restructuring advisers at Blackstone (BX) and other firms on how to handle its $3.8B long-term debt, reports the Wall Street Journal, citing people familiar with the matter. The Journal notes that Samson previously expressed interest in selling some oil and gas fields. Reference Link
09:41 EDTJNJHospira launches generic Remicade, WSJ says
Subscribe for More Information
08:03 EDTJNJJohnson & Johnson forms new health and wellness platform
Subscribe for More Information
06:52 EDTJNJPharmacyclics downgraded to Hold from Buy at WallachBeth
Subscribe for More Information
February 25, 2015
14:47 EDTJNJPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:10 EDTJNJPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
12:54 EDTJNJPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTJNJPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
09:13 EDTBXBlackstone seeks coalition partners to invest outside its funds, WSJ reports
Subscribe for More Information
06:31 EDTDHRDanaher increases quarterly dividend 35% to 13.5c
Subscribe for More Information
February 24, 2015
15:07 EDTCGCarlyle, Cap Gemini talks to buy CSC have 'fizzled,' Reuters says
Consulting company Cap Gemini and private equity firm Carlyle Group (CG) previously held talks about a potential acquisition of Computer Sciences Corp. (CSC), though the talks have since "fizzled," reported Reuters, citing people familiar with the matter. CSC is now working with Royal Bank of Canada (RY) to review its options, the report added. Reference Link
14:56 EDTCGCarlyle, Cap Gemini talks to buy CSC have 'fizzled,' Reuters says
Subscribe for More Information
February 23, 2015
13:49 EDTCGCarlyle Group, Advent mull sale of H.C. Starck, Bloomberg reports
Subscribe for More Information
08:42 EDTBXBlackstone Energy Partners II is oversubscribed at $4.5B
Blackstone announced the commencement of the investment period for its second energy-focused private equity fund, Blackstone Energy Partners II, with total commitments of $4.5B. BEP II received significant interest from both existing and new investors, with demand well surpassing the fund’s $4.5B hard cap. Investors in the fund include a diverse group of U.S. state pension funds, corporate pension funds, sovereign wealth funds, insurance companies, endowments, foundations and family offices. Like its predecessor fund BEP I, a $2.4B fund that had its final close in September 2012, BEP II will invest in control-oriented equity and equity-linked interests in companies, assets and development projects in the energy and natural resources sector on a global basis. To date, Blackstone’s energy-focused private equity team of professionals has deployed over $8B in this strategy. Blackstone's $16B diversified global private equity fund will continue to invest alongside BEP II in energy transactions on a 50/50 basis.
February 22, 2015
12:51 EDTJNJJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
07:23 EDTJNJAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use